Barry S Coller

USPTO Granted Patents = 24 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 1.8

ph-index = 11

Forward Citations = 369(Granted Patents)

Location History:

Dix Hills, NY (US) (1993 - 1999)
New York, NY (US) (1998 - 2021)

Company Filing History:

10 out of 1,997

The State University of New York

patents

6 out of 712

The Rockefeller University

Icahn School of Medicine at Mount Sinai

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

7. 2 out of 242

Mount Sinai School of Medicine

patents

8. 1 out of 2,896

The General Hospital Corporation

patents

where one patent can have more than one assignee

Years Active: 1993-2021

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11192889 - Tetrahydronaphthyridinepentanamide integrin antagonists (2021-12-07),

2. 10450375 - Methods of treating sickle cell disease (2019-10-22),

3. 9532989 - Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines (2017-01-03),

4. 9506938 - Methods for measuring platelet reactivity of individuals treated with drug eluting stents (2016-11-29),

5. 9341637 - Controlled platelet activation to monitor therapy of ADP antagonists (2016-05-17),

6. 9303044 - 7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-A]pyrimidin-5-ones for the treatment of thrombotic disorders (2016-04-05),

7. 9073945 - Alpha-IIb-beta-3 inhibitors and uses thereof (2015-07-07),

8. 9066948 - Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines (2015-06-30),

9. 8574828 - Controlled platelet activation to monitor therapy of ADP antagonists (2013-11-05),

10. 8173661 - Alpha-IIB-beta-3 inhibitors and uses thereof (2012-05-08),

11. 7790362 - Controlled platelet activation to monitor therapy of ADP antagonists (2010-09-07),

12. 5976532 - Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or (1999-11-02),

13. 5877006 - DNAs encoding chimeric immunoglobulin light or heavy chains and (1999-03-02),

14. 5854005 - Platelet blockade assay (1998-12-29),

15. 5770198 - Platelet-specific chimeric 7E3 immunoglobulin (1998-06-23),

Title: The Innovative Contributions of Barry S. Coller in Medical Research

Introduction: Barry S. Coller, a prominent inventor based in New York, NY, has made significant strides in the field of medical research and pharmaceuticals. With a remarkable portfolio comprising 24 patents, Coller's innovations focus primarily on integrin antagonists and methods for treating complex diseases.

Latest Patents: Among his latest patents, Coller has developed tetrahydronaphthyridinepentanamide integrin antagonists. These compounds are designed to selectively inhibit αVβ3 without activating the αVβ3 receptor, which holds considerable promise for treating various conditions including osteoporosis, acute myelogenous leukemia, sickle cell disease, fibrosis, and ocular diseases such as age-related macular degeneration. Additionally, he has produced methods aimed at treating sickle cell disease by reducing the adherence between sickle red blood cells and leukocytes, ultimately addressing the complications associated with vaso-occlusion in sickle cell crises.

Career Highlights: Barry S. Coller has been influential in his field, having worked with prestigious institutions such as the State University of New York and The Rockefeller University. His pioneering research has contributed to a deeper understanding of integrin biology, paving the way for therapeutic interventions in various diseases.

Collaborations: Throughout his career, Coller has collaborated with notable colleagues, including Dennis A. Durbin and Marta Filizola. These partnerships have fostered an environment of innovation and scientific discovery, leading to advancements in treatments for life-threatening medical conditions.

Conclusion: Barry S. Coller stands out as a leading figure in the area of medical innovation. His extensive patent portfolio and ongoing contributions to scientific research reflect his dedication to addressing critical health challenges and improving patient care through advanced therapeutic techniques.

This text is generated by artificial intelligence and may not be accurate.